$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000114420415063796 Filed on November 09, 2015

Income Statement

Concept	2015 Q3	2014 Q3
Revenue	$2.947M	$1.256M
YoY Change	134.63%	8.37%
Cost Of Revenue	$1.415M	$682.0K
YoY Change	107.48%	10.53%
Gross Profit	$1.532M	$575.0K
YoY Change	166.43%	6.09%
Gross Profit Margin	51.99%	45.78%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$4.172M	$3.584M
YoY Change	16.43%	319.24%
% of Gross Profit	272.35%	623.23%
Depreciation & Amortization	$160.8K	$230.0K
YoY Change	-30.09%	109.09%
% of Gross Profit	10.5%	40.0%
Operating Expenses	$5.299M	$4.636M
YoY Change	14.3%	277.22%
Operating Profit	-$3.767M	-$4.061M
YoY Change	-7.24%	491.12%
Interest Expense	$63.82K	$70.08K
YoY Change	-8.92%	-72.62%
% of Operating Profit
Other Income/Expense, Net	$2.086M	$10.31M
YoY Change	-79.77%	-249.7%
Pretax Income	-$1.681M	$21.38M
YoY Change	-107.86%	-321.89%
Income Tax	$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$1.681M	$6.248M
YoY Change	-126.9%	-164.83%
Net Earnings / Revenue	-57.04%	497.45%
Basic Earnings Per Share	-$0.01	$0.04
Diluted Earnings Per Share	-$0.01	-$0.01
COMMON SHARES
Basic Shares Outstanding	665.3M shares	577.7M shares
Diluted Shares Outstanding	823.5M shares	739.9M shares

Balance Sheet

Concept	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.030M	$7.630M
YoY Change	18.35%	890.91%
Cash & Equivalents	$9.031M	$7.627M
Short-Term Investments
Other Short-Term Assets	$300.0K	$460.0K
YoY Change	-34.78%	187.5%
Inventory	$3.353M	$2.520M
Prepaid Expenses
Receivables	$1.416M	$1.100M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$14.10M	$11.71M
YoY Change	20.37%	257.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.555M	$5.170M
YoY Change	46.12%	31.21%
Goodwill
YoY Change
Intangibles	$6.400M
YoY Change
Long-Term Investments	$50.00K	$40.00K
YoY Change	25.0%	-98.8%
Other Assets	$649.2K	$610.0K
YoY Change	6.42%	12.96%
Total Long-Term Assets	$1.960M	$12.18M
YoY Change	-83.91%	-13.82%
TOTAL ASSETS
Total Short-Term Assets	$14.10M	$11.71M
Total Long-Term Assets	$1.960M	$12.18M
Total Assets	$28.70M	$23.89M
YoY Change	20.13%	37.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.610M	$2.680M
YoY Change	34.7%	38.86%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$410.0K	$670.0K
YoY Change	-38.81%	-89.5%
Long-Term Debt Due	$470.0K	$334.9K
YoY Change	40.32%	-90.12%
Total Short-Term Liabilities	$4.508M	$3.810M
YoY Change	18.32%	-67.5%
LONG-TERM LIABILITIES
Long-Term Debt	$2.065M	$233.8K
YoY Change	783.13%
Other Long-Term Liabilities	$549.5K	$73.38M
YoY Change	-99.25%	76275.44%
Total Long-Term Liabilities	$11.70M	$75.45M
YoY Change	-84.5%	553.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.508M	$3.810M
Total Long-Term Liabilities	$11.70M	$75.45M
Total Liabilities	$16.21M	$79.25M
YoY Change	-79.55%	240.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$136.9M	-$208.0M
YoY Change	-34.17%	51.68%
Common Stock	$116.9M	$153.0M
YoY Change	-23.59%	16.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K
YoY Change	0.0%	0.0%
Treasury Stock Shares	100.0K shares	100.0K shares
Shareholders Equity	-$20.36M	-$55.36M
YoY Change
Total Liabilities & Shareholders Equity	$28.70M	$23.89M
YoY Change	20.13%	37.2%

Cashflow Statement

Concept	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$1.681M	$6.248M
YoY Change	-126.9%	-164.83%
Depreciation, Depletion And Amortization	$160.8K	$230.0K
YoY Change	-30.09%	109.09%
Cash From Operating Activities	-$3.480M	-$4.430M
YoY Change	-21.44%	381.52%
INVESTING ACTIVITIES
Capital Expenditures	-$700.0K	-$320.0K
YoY Change	118.75%	255.56%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$50.00K
YoY Change	-100.0%	-200.0%
Cash From Investing Activities	-$700.0K	-$380.0K
YoY Change	84.21%	660.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$915.0K
YoY Change
Cash From Financing Activities	1.600M	4.260M
YoY Change	-62.44%	182.12%
NET CHANGE
Cash From Operating Activities	-3.480M	-4.430M
Cash From Investing Activities	-700.0K	-380.0K
Cash From Financing Activities	1.600M	4.260M
Net Change In Cash	-2.580M	-550.0K
YoY Change	369.09%	-201.85%
FREE CASH FLOW
Cash From Operating Activities	-$3.480M	-$4.430M
Capital Expenditures	-$700.0K	-$320.0K
Free Cash Flow	-$2.780M	-$4.110M
YoY Change	-32.36%	395.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	us-gaap	Inventory Net InventoryNet	3032002	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7464180	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9031088	USD
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	388959	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	649163	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	12330684	USD
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	388959	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	806019	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1446441	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	3353313	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	295108	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	388061	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	14095395	USD
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1415886	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7554519	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6401802	USD
CY2015Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6399667	USD
CY2015Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6381774	USD
CY2015Q3	us-gaap	Security Deposit SecurityDeposit	48714	USD
CY2015Q1	us-gaap	Security Deposit SecurityDeposit	198481	USD
CY2015Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	211490	USD
CY2015Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	218579	USD
CY2015Q1	us-gaap	Assets Assets	25920279	USD
CY2015Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	220000	USD
CY2015Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	210000	USD
CY2015Q3	eltp	Short Term Loans And Current Portion Of Long Term Debt ShortTermLoansAndCurrentPortionOfLongTermDebt	251835	USD
CY2015Q1	eltp	Short Term Loans And Current Portion Of Long Term Debt ShortTermLoansAndCurrentPortionOfLongTermDebt	265165	USD
CY2015Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	411709	USD
CY2015Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	583071	USD
CY2015Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3611073	USD
CY2015Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3997528	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4507950	USD
CY2015Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1845000	USD
CY2015Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	2065000	USD
CY2015Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	118890	USD
CY2015Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	125557	USD
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	549486	USD
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	629138	USD
CY2015Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11697592	USD
CY2015Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	20582268	USD
CY2015Q3	us-gaap	Liabilities Liabilities	16205542	USD
CY2015Q1	us-gaap	Liabilities Liabilities	25651365	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	681759	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	631162	USD
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	116204254	USD
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	108819628	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136943114	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143875035	USD
CY2015Q3	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2015Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	-20363941	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	-34731086	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28698744	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25920279	USD
CY2015Q3	us-gaap	Deferred Long Term Liability Charges DeferredLongTermLiabilityCharges	9184216	USD
CY2015Q3	us-gaap	Assets Assets	28698744	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5069097	USD
	us-gaap	Interest Expense InterestExpense	136507	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	9074777	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	565150231	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	656141476	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	733912128	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	814306324	shares
	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	1670678	USD
	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3248	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2750	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12647269	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8439101	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	16978014	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2015Q1	us-gaap	Deferred Long Term Liability Charges DeferredLongTermLiabilityCharges	17762573	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2780142	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	171470	USD
	eltp	Stock Issued During Period Value Execution Of Warrants StockIssuedDuringPeriodValueExecutionOfWarrants	2328255	USD
	eltp	Park Capital Purchase Agreement ParkCapitalPurchaseAgreement	0	USD
	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	1799971	USD
	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	4228968	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	613128	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	547311	USD
	us-gaap	Contracts Revenue ContractsRevenue	5000	USD
	us-gaap	Contracts Revenue ContractsRevenue	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	2418099	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	9776279	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1410199	USD
	us-gaap	Cost Of Revenue CostOfRevenue	2611497	USD
	us-gaap	Gross Profit GrossProfit	1007900	USD
	us-gaap	Gross Profit GrossProfit	7164782	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7623403	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1329268	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	77143	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	470696	USD
	us-gaap	Operating Expenses OperatingExpenses	9500511	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8492611	USD
	us-gaap	Interest Expense InterestExpense	148281	USD
	us-gaap	License And Maintenance Revenue LicenseAndMaintenanceRevenue	5000000	USD
	us-gaap	License And Maintenance Revenue LicenseAndMaintenanceRevenue	0	USD
CY2014Q3	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	850934	USD
CY2015Q3	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	2553195	USD
CY2014Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	405483	USD
CY2015Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	143312	USD
CY2014Q3	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2015Q3	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1256417	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	2696507	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	681669	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	1414529	USD
CY2015Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	3015384	USD
CY2015Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2850459	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	574748	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	1281978	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3583563	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4172419	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	722229	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	881566	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	53481	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	80992	USD
CY2014Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	276812	USD
CY2015Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	164340	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	4636085	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	5299317	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4061337	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4017339	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	70075	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	63824	USD
CY2014Q3	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	10379665	USD
CY2015Q3	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	2149787	USD
CY2014Q3	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
CY2015Q3	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10309590	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2085963	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	21379824	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7002782	USD
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	577691292	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	665330431	shares
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	739869496	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	823495279	shares
CY2015Q3	us-gaap	License And Maintenance Revenue LicenseAndMaintenanceRevenue	0	USD
CY2014Q3	us-gaap	License And Maintenance Revenue LicenseAndMaintenanceRevenue	0	USD
CY2015Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	160080	USD
CY2015Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	58771	USD
CY2015Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	177849	USD
CY2015Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	122772	USD
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	10721215	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1646437	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6966966	USD
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	158164848	shares
CY2015Q3	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	-2921619	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4081161	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4131412	USD
CY2015Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	158164848	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4355500	shares
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3226667	shares
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	51723	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3862455	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	257601	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	90427	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	63003	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-10991	USD
CY2015Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	45214	USD
CY2014Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	45214	USD
CY2015Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	31533	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS INC /NV/
	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	ELTP
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	684756279	shares
CY2015Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	272620	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6392827	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6074117	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2015Q3	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	142963	USD
CY2015Q1	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	135874	USD
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	690000000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	681756279	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	631160701	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	680756279	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	630060701	shares
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-1931376	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	6248253	USD
	us-gaap	Net Income Loss NetIncomeLoss	6931920	USD
	us-gaap	Net Income Loss NetIncomeLoss	4154659	USD
	eltp	Stock Issued During Period Value Payment Of Directors Fees StockIssuedDuringPeriodValuePaymentOfDirectorsFees	12500	USD
	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	2142857	USD
CY2015Q3	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	-5071406	USD
CY2014Q3	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	15131571	USD
	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	12823356	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	325799	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	435537	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	586167	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	679771	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	171470	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	83333	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	5189	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	798	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	752	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	495753	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	830515	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	756053	USD
	us-gaap	Depreciation Depreciation	463609	USD
CY2015Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	1960000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	16364	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4578453	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5463882	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1566908	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	685301	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6941777	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7627078	USD
	us-gaap	Interest Paid InterestPaid	110372	USD
	us-gaap	Interest Paid InterestPaid	141342	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	65794	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-147650	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	365708	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	321311	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	591130	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-242720	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	60861	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-960122	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-183608	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-6667	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-6667	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1588019	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8641036	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1423526	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	1405633	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	1005087	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17893	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8549	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	123909	USD
	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	5000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2780142	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6227485	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2328255	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	290231	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-171362	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	137579	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	148582	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	65049	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	2272500	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	210000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1110000	USD
	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	117095	USD
	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2015Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2065000	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6349917	USD
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	17893	USD
CY2015	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	31855	USD
	us-gaap	Finite Lived Intangible Assets Amortization Method FiniteLivedIntangibleAssetsAmortizationMethod	straight-line method
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13947346	USD
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12475938	USD
	us-gaap	Depreciation Depreciation	318711	USD
CY2014Q3	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	25511236	USD
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	23944980	USD
CY2014Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	162178204	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	162178204	shares
CY2015Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2015Q3	eltp	Proceeds From Sale Of Generic Products ProceedsFromSaleOfGenericProducts	4776000	USD
	eltp	Proceeds From Sale Of Generic Products ProceedsFromSaleOfGenericProducts	2696000	USD
CY2015Q3	eltp	Proceeds From Sale Of Branded Products ProceedsFromSaleOfBrandedProducts	5000000	USD
	eltp	Proceeds From Sale Of Branded Products ProceedsFromSaleOfBrandedProducts	5000000	USD
CY2014Q3	eltp	Proceeds From Sale Of Branded Products ProceedsFromSaleOfBrandedProducts	5000000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	205878	USD
CY2015Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	37027	USD
	us-gaap	Description Of Lessee Leasing Arrangements Operating Leases DescriptionOfLesseeLeasingArrangementsOperatingLeases	include an initial term that expires on December 31, 2016, and the Company has the option to renew the lease for two additional terms of five years each.
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	100	shares
	eltp	License Agreement Term LicenseAgreementTerm	Elite is entitled to 15% of the profits achieved from the commercial sales of this product for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.
	us-gaap	Revenue Recognition Milestone Method Milestone RevenueRecognitionMilestoneMethodMilestone	The milestones, totaling $500k, consist of amounts due upon the first shipment of each identified product, as follows: Phentermine 37.5mg tablets ($145k), Phentermine 15 &amp; 30mg capsules ($45k), Hydromorphone 8mg ($125k), Naltrexone 50mg ($95k) and the balance of $95k due in relation to the first shipment of generic products which still require marketing authorizations from the FDA, and to which there can be no assurances of such marketing authorizations being granted and accordingly there can be no assurances that the Company will earn and receive these milestone amounts.
CY2015Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
	eltp	Proceeds From Sale Of Branded Products ProceedsFromSaleOfBrandedProducts	5000000	USD
CY2014Q3	eltp	Proceeds From Sale Of Generic Products ProceedsFromSaleOfGenericProducts	4776000	USD
	eltp	Proceeds From Sale Of Generic Products ProceedsFromSaleOfGenericProducts	2696000	USD
CY2015Q3	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	15000	sqft
CY2015Q3	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	35000	sqft
	eltp	Lease Period Description LeasePeriodDescription	The lease term began on July 1, 2010.

Files In Submission

Name	View Source	Status
0001144204-15-063796-index-headers.html	Edgar Link	pending
0001144204-15-063796-index.html	Edgar Link	pending
0001144204-15-063796.txt	Edgar Link	pending
0001144204-15-063796-xbrl.zip	Edgar Link	pending
eltp-20150930.xml	Edgar Link	completed
eltp-20150930.xsd	Edgar Link	pending
eltp-20150930_cal.xml	Edgar Link	unprocessable
eltp-20150930_def.xml	Edgar Link	unprocessable
eltp-20150930_lab.xml	Edgar Link	unprocessable
eltp-20150930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v423581_10q.htm	Edgar Link	pending
v423581_ex31-1.htm	Edgar Link	pending
v423581_ex31-2.htm	Edgar Link	pending
v423581_ex32-1.htm	Edgar Link	pending
v423581_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2015 Q3 Form 10-Q Financial Statement

#000114420415063796 Filed on November 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2015 Q3 Form 10-Q Financial Statement

#000114420415063796 Filed on November 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp